ExpreS2ion Biotechnologies – Presentation of Year-end report 2022
ExpreS2ion Biotechnologies is expected to report its financial results for 2022 on 9 February 2023. In a virtual live event on 14 February at 11:30, you can meet and ask questions to the company’s CEO Bent Frandsen and CFO Keith Alexander, who will present the year-end report. Awaiting the phase 3 data on the COVID-19 vaccine candidate, which is expected in Q1 2023, attention could be directed to the recent news flow, including the publishing of phase 1 clinical trial of the COVID-19 vaccine ABNCoV2 in the journal The Lancet Microbe, the appointment of a new Chief Scientific Officer, and the research collaboration with Evaxion Biotech.
On the result side, there are no surprises expected. Growth will be dampened by a shift in focus from its legacy CRO business to developing pipeline candidates, and costs will be at a higher level due to increased R&D spending.
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system. Currently, the company has a late-stage pipeline of vaccines against COVID-19 and an early-stage pipeline for breast cancer, influenza, and malaria.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 11:49, 24 January 2023.